

## **Bone Health and Orthopedic Risk Management in Breast Cancer Patients**

Po-Hsiang Huang , M.D.

Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. Bone metastases predispose patients to pain, the development of skeletal-related events (SREs), and even disability. The goal of bone-targeted agent (BTA) therapy is to prevent SREs and improve patients' quality of life while minimizing treatment-related complications.

Dr. Huang will cover the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available BTAs in breast cancer, focusing on bisphosphonates and receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. He will also provide a brief guideline update, discuss novel treatment strategies, and most importantly share his experience on how to implement them in our daily practice to maximize patient outcomes.